Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Net Income (2016 - 2025)

Angiodynamics (ANGO) has disclosed Net Income for 16 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 40.86% year-over-year to -$6.4 million, compared with a TTM value of -$27.7 million through Nov 2025, up 87.67%, and an annual FY2025 reading of -$34.0 million, up 81.56% over the prior year.
  • Net Income was -$6.4 million for Q4 2025 at Angiodynamics, up from -$10.9 million in the prior quarter.
  • Across five years, Net Income topped out at $45.9 million in Q3 2023 and bottomed at -$187.7 million in Q1 2024.
  • Average Net Income over 5 years is -$16.9 million, with a median of -$9.0 million recorded in 2022.
  • The sharpest move saw Net Income surged 452.85% in 2023, then crashed 1879.29% in 2024.
  • Year by year, Net Income stood at -$8.4 million in 2021, then fell by 1.62% to -$8.5 million in 2022, then tumbled by 242.3% to -$29.0 million in 2023, then soared by 63.03% to -$10.7 million in 2024, then surged by 40.86% to -$6.4 million in 2025.
  • Business Quant data shows Net Income for ANGO at -$6.4 million in Q4 2025, -$10.9 million in Q3 2025, and -$6.0 million in Q2 2025.